Literature DB >> 9262606

Pulmonary valve replacement late after repair of tetralogy of Fallot.

I M Yemets1, W G Williams, G D Webb, D A Harrison, P R McLaughlin, G A Trusler, J G Coles, I M Rebeyka, R M Freedom.   

Abstract

BACKGROUND: Pulmonary valve incompetence is usually well tolerated after tetralogy of Fallot repair but may result in late progressive right heart failure as manifested by increasing fatigue, dyspnea, and frequently arrhythmias.
METHODS: All patients who underwent pulmonary valve replacement in our center late after repair of tetralogy of Fallot were reviewed.
RESULTS: Eighty-five patients had elective pulmonary valve replacement late (median, 9.3 years) after repair. Operative risk was low (1.1%). Ninety percent of survivors are in New York Heart Association class I. Survival 10 years after pulmonary valve replacement is 95%, with 86% of the patients free of reoperation for valve failure.
CONCLUSIONS: Pulmonary valve replacement is infrequently required after repair of tetralogy of Fallot. Pulmonary valve replacement may be performed electively with little risk; it improves symptoms of right heart failure and provides satisfactory long-term survival with low risk of early valve failure. As the population of patients who have had repair of tetralogy of Fallot ages, pulmonary valve replacement will become a more frequent consideration.

Entities:  

Mesh:

Year:  1997        PMID: 9262606     DOI: 10.1016/S0003-4975(97)00577-8

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  27 in total

Review 1.  Management of pulmonary regurgitation after tetralogy of fallot repair.

Authors:  Thomas P Graham
Journal:  Curr Cardiol Rep       Date:  2002-01       Impact factor: 2.931

2.  Management of Adults with Operated Tetralogy of Fallot.

Authors:  Sonya V. Babu-Narayan; Michael A. Gatzoulis
Journal:  Curr Treat Options Cardiovasc Med       Date:  2003-10

3.  Isolated pulmonary valve replacement: analysis of 27 years of experience.

Authors:  Shigehiko Tokunaga; Munetaka Masuda; Akira Shiose; Yukihiro Tomita; Shigeki Morita; Ryuji Tominaga
Journal:  J Artif Organs       Date:  2008-10-05       Impact factor: 1.731

4.  Influence of pressure load on durability of pulmonic xenobioprostheses in young adults.

Authors:  Nobuyuki Takagi; Kazutoshi Tachibana; Yasuko Miyagi; Akihiko Yamauchi; Satoshi Muraki; Tetsuya Higami
Journal:  J Artif Organs       Date:  2011-07-07       Impact factor: 1.731

5.  Porcine bioprosthetic valve in the pulmonary position: mid-term results in the right ventricular outflow tract reconstruction.

Authors:  Alessandro Giamberti; Massimo Chessa; Matteo Reali; Alessandro Varrica; Halkawt Nuri; Giuseppe Isgrò; Alessandro Frigiola; Marco Ranucci
Journal:  Pediatr Cardiol       Date:  2013-02-24       Impact factor: 1.655

6.  Right Ventricular Mass is Associated with Exercise Capacity in Adults with Repaired Tetralogy of Fallot.

Authors:  Shamus O'Meagher; Martin Seneviratne; Michael R Skilton; Phillip A Munoz; Peter J Robinson; Nathan Malitz; David J Tanous; David S Celermajer; Rajesh Puranik
Journal:  Pediatr Cardiol       Date:  2015-03-21       Impact factor: 1.655

7.  Pulmonic regurgitation and management challenges in the adult with tetralogy of fallot.

Authors:  Emily Ruckdeschel; Joseph D Kay
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-06

8.  Triple valve replacement late after tetralogy of Fallot repair: report of a case.

Authors:  Nobuchika Ozaki; Nobuhiko Mukohara; Masato Yoshida; Tsutomu Shida
Journal:  Surg Today       Date:  2008-10-29       Impact factor: 2.549

9.  Management after childhood repair of tetralogy of fallot.

Authors:  Jamil Aboulhosn; John S Child
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-12

10.  Coexistence of mitral regurgitation and pulmonary regurgitation in an adult with surgically corrected tetralogy of Fallot.

Authors:  Dimitrios Z Mytas; Meletios A Kanakis; Lamprini K Kosma; Fotios A Mitropoulos
Journal:  BMJ Case Rep       Date:  2012-12-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.